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Despite undisputable benefits, conventional pacemaker therapy is associatedwith specific complications related to the subcutaneous device and
the transvenous leads. Recently, two miniaturized leadless pacemakers, NanostimTM (St. Jude Medical) and MicraTM (Medtronic), which can be
completely implanted inside the right ventricle using steerable delivery systems, entered clinical application. TheWiCSTM-cardiac resynchronisa-
tion therapy (CRT) system (wireless cardiac stimulation for CRT, EBR Systems) delivers leadless left ventricular endocardial stimulation for
cardiac resynchronization. In addition to obvious cosmetic benefits, leadless pacing systemsmay have the potential to overcome some complica-
tions of conventional pacing. However, acute and long-term complications still remains to be determined, as well as the feasibility of device ex-
plantation years after device placement.
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Introduction
Since the first report on the successful use of an external cardiac
pacemaker system by Alber S. Hyman in 1932, the first complete im-
plantation of an epicardial pacing system by Rune Elmquist and A˚ke
Senning in 1958, and the implantation of a transvenous temporary
pacing lead the same year by Seymour Furman, pacemaker therapy
has evolved considerably. Advances in battery and circuit technology
have led to programmable multichamber pacemakers with a lifespan
of 7–10 years. Conventional subcutaneous pacemaker implantation
and transvenous lead placement requires a surgical procedure.
Despite the technological strides made over the last decades, con-
ventional pacemaker treatment continues tobe associatedwithcom-
plications. Immediate post-operative adverse events occur in 10%
of patients and are either related to the device (haematoma, skin
erosion, pocket infection) or result from transvenous lead placement
(pneumothorax, cardiac perforation, lead dislodgement).1
The leads are the most vulnerable component of the system,
because they can fracture, develop insulation defects, connector
issues, or become infected. Due to steadily increasing numbers of
implantations and the higher life expectancy of patients, it is to be
expected that the total number of long-term complications will
markedly increase.
As early as 1970, miniaturized batteries and electronic circuits led
to the development of concepts of pacemakers that could be com-
pletely implanted inside the right ventricle (RV).2,3 Size, battery lon-
gevity, and secure fixation were the key issues. Various shapes and
battery types, including nuclear batteries, were tested. Despite the
remarkable technological advances at that time, intracardiac pace-
makers did not make it into clinical practice. Subsequently, various
concepts aiming toeliminate theneed forpacemaker leadswereeval-
uated. Gene and stem-cell therapy for treating cardiac rhythm and
conduction disorders have been studied in the experimental
setting. However, these biological pacemakers are still in their early
phases of development and have not yet been tested in humans.4
Leadless devices were usually based on external wireless energy
transmission to an intracardiac receiver, i.e. they could not be com-
pletely implanted in the heart.5–7
A completely implantable system into the RV) became reality in
2012 when the NanostimTM Leadless Pacemaker System (St. Jude
Medical, Sylmar, CA, USA) first became available. One year later,
the MicraTM Transcatheter Pacing System (Medtronic, Minneapolis,
MN, USA) was introduced. The currently available completely intra-
cardiac pacemaker systems are suitable for patients who have an in-
dication for VVIR pacing. In addition to the cosmetic advantage, the
leadless design and lack of a surgically created pocket eliminate the
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main sources of complications associated with conventional pace-
maker implantation.
A different concept of leadless pacing is pursued by the ultrasound-
based WiCSTM system (Wireless Cardiac Stimulation; EBR Systems,
Sunnyvale, CA, USA). Cardiac resynchronisation therapy (CRT) is
still associated with severe limitations, primarily a persistent 30–40%
non-responder rate and a rate of up to 10% of chronic left ventricular
(LV) lead failure.8–12 Targeting of optimal LV pacing sites is limited by
theanatomyof thecoronarysinustributaries.Leftventricularendocar-
dial pacing is another approach, aiming for better clinical results with
CRT by improving hemodynamics by optimizing the LV pacing
sites.13–15 Historically, LV endocardial pacing has been accomplished
via an atrial transseptal approach16,17 and more recently via puncture
of the interventricular septum.18 Both techniques are limited by pro-
cedural issues and the long-term risk of thromboembolic events
related to the lead permanently residing inside the LV. The WiCSTM
system is intended toprovide an alternative by pacing LVendocardially
for CRTwith a device receiving its energy from a subcutaneous ultra-
sound transmitter.19 This system is potentially suitable for patients re-
quiring CRT especially if conventional LV lead placement failed.
In this review, we summarize and discuss technological and clinical
aspects of the three systems mentioned above.
Technological aspects of leadless
pacing
Leadless systems for right ventricle pacing
There are two leadless pacing systems currently available, which can
be completely implanted in the right ventricle: theNanostimTM lead-
less cardiac pacemaker (LCP) (Figure 1) and the MicraTM transcath-
eter pacing system (TPS) (Figure 2).
Characteristics of both systems are compared in Table 1.
Both systems offer pacing features similar to conventional VVIR
pacemakers including rate response algorithms. Moreover, a
steroid-eluting tip is incorporated to reduce inflammation. Although
these devices are significantly smaller than conventional pacing
systems, the predicted longevities are10 years. This is comparable
to the longevity of a standard pacemaker and is made possible by a
design optimizing both energy consumption and the electrode/
tissue interface. Theproximal endof the devices incorporate amech-
anism for recapturing the systems if repositioning becomesnecessary
after implantation or if devices need to be retrieved. To date no data
exist for the removal of chronic implanted systems. In the event of
battery depletion, removal of the leadless pacemaker may be
unnecessary, as an option may be to simply implant an additional
device. How thiswill affect cardiac function, and howmany additional
devices may be implanted, remains however to be determined.
Main differences between the systems are related to the fixation
and programming of the devices.
The primary fixation mechanism of the LCP device is a screw-in
helix with a maximum penetration depth in tissue of 1.3 mm. Three
nylon tines provide a secondary fixation mechanism by avoiding
Docking button Battery Electronics
Fixation sutures
Helix
Figure 1 The St. Jude Medical NanostimTM leadless pacemaker
(reproduced with permission from St. Jude Medical Inc.).
Figure 2 The Medtronic MicraTM Transcatheter Pacing System
(reproduced with permission from Medtronic Inc.).
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unscrewing of the helix. The tip electrode is a steroid-eluting disc
located at the centreof the fixating helix. The ring electrode is the un-
coated part of the titanium pacemaker case. A dedicated program-
mer connected to the MerlinTM patient care system communicates
with the device using conducted communication and displays the
intracardiac electrogram and the status of the implanted device; it
is also used for programming the parameter settings. Signal transmis-
sion from the programmer to the implanted LCP is accomplished by
applying subliminal 250 kHz pulses to skin leads. The programmer
automatically selects theoptimal pairof skin leads for communication
with the LCP. Except for this special type of signal transmission, the
programmer uses the same operating principles as conventional
pacemaker programmers.
The TPS is currently the smallest standalone system available. The
fixation mechanism comprises four flexible self-expanding nitinol
tines, which hook into the myocardium and anchor the device inside
the right ventricle. The tines are electrically inactive. A steroid-eluting
cathode located at the distal end of the device delivers the pacing
current, a titaniumnitride band on the casing acts as the anode. Thresh-
olds are measured automatically on a daily basis, with hourly checks of
the capture safetymargin. These checks do not require loss of capture.
Rate–response is provided by an accelerometer that filters out cardiac
motion with a bandpass filter. Monitoring and diagnostic features are
available, including rate histograms, pacing counters, evolution of
sensingamplitudes, capture thresholds, andpacing impedances.Follow-
up and programming are performed using the standard Medtronic
Model 2090 Programmer, similar to standard Medtronic pacemakers.
Leadless system for left ventricle pacing
The leadless ultrasound-based technology used by the WiCSTM
(Wireless Cardiac Stimulation; EBR Systems) system is designed
to achieve LV endocardial pacing. Leadless ultrasound pacing is
accomplished by transmitting ultrasound energy from a subcutane-
ous transmitter unit to an endocardial receiver unit. Fixation to the
endocardium is achieved by three self-expanding nitinol tines
mounted at the distal end of the device. ThewholeCRT systemcom-
prises (i) the LV endocardial unit, which receives ultrasound energy
and converts it to electrical energy for LV pacing, (ii) the subcutane-
ously implanted pulse generator and (iii) a conventional pacing
device. The subcutaneously implanted pulse generator comprises
the battery and the transmitter, connected by a cable. The transmit-
ter includes an ultrasound transducer array, the energy of which can
be focused for effective transmission to the LV endocardial unit. The
system detects RV stimulation provided by a co-implanted pace-
maker, CRT or implantable cardiac defibrillator (ICD) device, and
applies a synchronized LV stimulus after a 3 ms delay.
Implantation of leadless
pacemakers
NanostimTM leadless cardiac pacemaker
and MicraTM transcatheter pacing system
implantation procedure
For both systems, the intervention can be performed in the cathlab
using a fluoroscopic imaging system and local anaesthesia. After
puncture of the femoral vein the delivery systemwith the pacemaker
mounted on a deflectable tip is advanced under fluoroscopic guid-
ance through the inferior vena cava to the right atrium. From there
the system is advanced to the RV via the tricuspid valve using the
deflectable delivery system. The LCP is implanted into the endocar-
dium in the apico-septal area by rotating the screw-in helix with 1.25
turns. For fixation of theTPS at the endocardiumof the target region,
the tines are deployed by retracting a protective outer sheath. After
fixation, the pacemaker is undocked from the delivery systembut still
connected via tethers. This allows themeasurementof pacing thresh-
old, Sensing amplitude and impedance without applying force on the
device. In the case of inappropriate electrical values, the pacemaker
can be repositioned. Adequate fixation is confirmed for both
systems by performing the so called tug test via the delivery system
under fluoroscopic visualization. If electrical performance and stabil-
ity of the device is confirmed, itmay be finally released. Figure 3 shows
as an example the implant steps for the LCP.
WiCSTM implant procedure
Individual assessment of potential acoustic windows is performed
preoperatively by standard echocardiography to determine the
best subcutaneous position of the transmitter. An optimal acoustic
path should be free of lung and bone tissue and provide an unob-
structed pathway from the transducer to the heart. The best acoustic
window, which is known to vary with patient movement and respir-
ation, is usually found in the 4th, 5th, and/or 6th intercostal space
lateral of the left parasternal border.20 The receiver/pulse generator
is delivered retrogradely across the aortic valve to the desired endo-
cardial pacing site of the left ventricle. Fixation to the endocardium is
achievedwith three self-expanding nitinol tinesmounted at the distal
end of the device.
Scientific data
Data for NanostimTM leadless cardiac
pacemaker
The LEADLESS trial21 was a prospective, multicentre, non-
randomized trial conducted at three European centres. Patients
were enrolled from December 2012 to April 2013. The main inclu-
sion criteria were age .18 years and a clinical indication for single-
chamber VVIR pacing. Patients were excluded if they were pacemaker
dependent, had a mechanical tricuspid valve prosthesis, pulmonary
hypertension, previously implanted pacemaker/defibrillator leads,
or an inferior vena cava filter. After implantation of a LCP system,
follow-up was performed pre-discharge and at 2, 6, and 12 weeks
post-implant. The primary endpoint was freedom from serious
adverse device events (SADE) at 90 days. Secondary endpoints
included implant success rate and pacemaker performance charac-
teristics (e.g. pacing thresholds, battery voltage, R-wave amplitude).
A total of 33 patients (mean age 77+ 8 years, 67% male) received
an LCP system. Implant success rate was 97% (n ¼ 32), and the ma-
jority of patients (n ¼ 23, 70%) did not require repositioning of the
LCP after its initial deployment. The overall complication-free rate
was 94% (31/33). Therewere two SADE. A 70-year-oldmale experi-
enced cardiac tamponade with hemodynamic collapse during LCP
J. Sperzel et al.1510
implantation. Although emergency surgery was successful and the
patient was recovering, he suffered a middle cerebral artery ischae-
mic stroke on post-procedureDay 5 and expired on post-procedure
dayeighteen. The second SADEwas due to inadvertent placement of
the LCP in the left ventricle through a persistent foramen ovale. The
device was retrieved and a second device was successfully placed in
the right ventricle during the same procedure. Three patients (9%)
were re-hospitalized; one patient because of an elevated inter-
national normalized ratio, one for acute exacerbation of chronic
obstructive lung disease, and one patient for syncope due to mono-
morphic ventricular tachycardia originating from a small scar in the
left ventricle. In the latter patient, the LCPwas retrieved and a transve-
nous ICD was placed. The mean R-wave amplitude, pacing threshold
and impedance were 8.3 mV, 0.80 V/0.4 ms, 773 Ohms at implant-
ation,which improved to9.7 mV, 0.41 V/0.4 ms, 719 Ohms at hospital
discharge and remained stable until 12weeks (10.7 mV, 046 V/0.4 ms,
627 Ohms). There were no reports of early battery depletion, or of
any issues with sensing or capture.
These results support the use of the LCP as an alternative to con-
ventional pacemaker systems. Continued evaluation is however
warranted to further characterize this system and follow-up of
the study cohort is ongoing. A limited market release is currently
underway, and resumed after temporary interruption and repeated
training of the implanting physicians, following two deaths due to
tamponade.
Current data on chronic LCP device retrieval are limited to results
from animal experiments.22 In this study, all devices implanted in 10
sheep could be explanted after 5 months without difficulties.
Data for MicraTM transcatheter pacing
system
An initial feasibility studywas performed in 16 sheep implantedwith a
wired capsule similar in design to the current device. The capsules
were placed in the apex of the right ventricle via a transvenous
route.23 Wires connected the capsules to standard pacemakers
used for measuring thresholds. After 24 weeks, the average pacing
threshold was 0.7+0.3 V/ 0.2 ms. No dislodgments or other com-
plications occurred. The good electrical parameters of the pacing
system were confirmed in a similar study in a sheep model with a
6-week follow-up.24 In another report, the TPS was implanted in
the right ventricular apex of 10 mini-pigs.25 Capture thresholds
were good at the time of implantation and at the 12 week follow-up
(0.58+ 0.17 V/0.24 ms and 0.94+0.46/ 0.24 ms, respectively). Ex-
traction of the device was assessed in four sheep,26 each implanted
with a TPS prototype equipped with a retrieval/extraction system
at the proximal end. Prototype extraction tools (steerable sheaths
and snares) were developed by Cook Medical (Bloomington, IN,
USA). After 18 months, all four devices were successfully retrieved
and had remained relatively free fromencapsulation at their proximal
ends. The flexible nitinol tines permitted extraction by simple trac-
tion. Histological analyses demonstrated only minimal damage to
cardiac tissues.However, longer-termdata are still required todeter-
mine whether the device can be safely removed several years after
implantation.
Currently, the Micra clinical trial is enrolling patients, and the first
human implantation was performed in December 2013. This single-
arm multicentre global clinical trial will enrol up to 780 patients at
Figure 3 Leadless cardiac pacemaker implantation steps. (A) A venogrammay optionally be performed; (B) The LCP is positioned into the RV by
deflecting the catheter andplaced0.5–1 cm fromtheRVapex; (C andD) Protective cover is pulled back to expose the flexible part of the catheter;
(E) The pacemaker is undocked from the delivery catheterwhile a tethered connection ismaintained. In case the position is suboptimal, the LCP can
be reengaged, unscrewed, and repositioned. (F) The LCP is released by rotating the release knob of the catheter.
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50 centres. The primary endpoints after 6 months will be safety
(major complication-free rate) and efficacy (capture thresholds).
As part of the CE mark trial, the first four MicraTM TPS were suc-
cessfully implanted at theRVapexof four patients (ages 74–83 years,
2 females, 2 males) whose left ventricular ejection fraction was pre-
served and who had an indication for VVIR pacing.27 All procedures
were successful. The mean total procedure time was 47 min (range
37–73 min). The mean R-wave amplitude, pacing threshold and im-
pedance at implantation were 11.98 mV, 0.41 V/0.24 ms, and
713 Ohms respectively. During the first month after implantation,
no major complications occurred. Electrical parameters assessed at
the 1 month follow-up remained stable or improved to a mean
R-wave amplitude of 17.85 mV, a pacing threshold of 0.38 V/ 0.24 ms
and an impedance of 770 Ohms, respectively.
Data forWiCSTM
The WiSE-CRT study19 was a multicenter, prospective, non-
comparative first-in-man study in heart failure patientswith an indica-
tion for CRT. Primary objectives were the evaluation of safety
(device-related complications at 24 h and at 1-month follow-up)
and performance (effective biventricular pacing capture at 1 month)
of the WiCSTM device. Secondary objectives included a 6-month
analysis with preliminary efficacy endpoints. The study enrolled
17 patients (14 males, 12 with ischaemic cardiomyopathy), including
seven after unsuccessful CS lead implantation, two who failed to
benefit from conventional CRT, and eight with an indication for
CRTwho already had a pacemaker or an ICD.Mean baseline LVejec-
tion fractionwas 26%,meanQRS duration 176 ms, andmeanNYHA
class 3.1. Patientswere found tohave1–3 (mean 2.4+0.7) intercos-
tal spaceswith adequate acousticwindows. The 5th intercostal space
was suitable in all patients.
The WiCSTM system was successfully implanted in 13 patients
(76%). In four patients, no system was implanted due to procedure
and/or device-related pericardial effusions in three patients and
because of difficult system manoeuverability in one patient. Based
on recommendations given by the independentClinical EventsCom-
mittee, the sponsor discontinued the study on 16 March 2012.
The primary 1-month performance endpoint of effective biventri-
cular pacingwasdocumented in10of the12evaluablepatients (83%).
The secondary6-monthsperformanceendpointof effectivebiventri-
cular pacing was achieved in 11 of the 12 evaluable patients (92%).
Satisfactory performance meant statistically significant reduction of
the QRS duration and increased LV ejection fraction in conjunction
with clinical improvements including an improved NYHA functional
class, better self-assessment, and a higher clinical composite score.
These efficacy results were also observable in the subgroup of
patients who had failed to benefit from conventional CRT.
The WiSE-CRT study successfully documented the feasibility of
delivering LV endocardial-based CRT using wireless ultrasound
energy transfer. Preliminary results showed clinical benefits similar
to those observed during conventional atrio-biventricular pacing,
even in patients in whom conventional CRT had failed or could not
be initiated. Although this new technology remains very promising,
the delivery system requires improvements to reduce the incidence
of pericardial effusions. At a later time, further studies should re-
evaluate the safety and performance of this novel approach to LV
endocardial CRT.
Leadless pacing: current status
and future perspectives
Despite all the enthusiasm generated by these novel and remarkable
devices, it has to be stressed that the periprocedural risks associated
with implantation require attention. For twooutof the three systems,
clinical trials have either been terminated or put temporarily on hold
because of severe complications, including death. Cardiac perfor-
ation and tamponade seem to be issues that need to be addressed.
Device design, especially as regards the fixation mechanism, should
be carefully evaluated and if necessary adapted. A safe implantation
technique that is applicable to a broad clinical setting is desirable.
Thiswill also requirepropereducation and trainingof implanting phy-
sicians. Evaluationof these devices in clinical studies and registrieswill
be necessary to judge the benefit-to-risk profile, especially in the
long-term.
Future steps that may be taken are the development of leadless
multichamber devices that communicate with each other. Such
new devices would make leadless pacing suitable for a much larger
population. Boston Scientific is currently developing a leadless pace-
maker system, which may in the future be complementary to their
subcutaneous ICD (e.g. for delivering antitachycardia or antibrady-
cardia pacing, or forenhancing arrhythmiadiagnosis). Research is cur-
rently underway for harvesting kinetic energy from cardiacmotion to
fuel pacemaker function (similarly to automatic watches). Intracar-
diac pacemakers may one day profit from such technology, thereby
dispensing with the need for device replacement. Intravascular defi-
brillators are another next step, and initial results of an investigational
device have recently been published.28
Conclusions
The miniaturization of pacemaker components has allowed the de-
velopment of leadless pacemakers, and has marked a new era in
device therapy. Many of the problems inherent to conventional
pacing, such as pocket issues and lead dysfunction, may thus be
avoided. In addition to the cosmetic advantage, the implantation
procedure may be simplified, especially in the case of difficult
venous access via the thoracic veins. Currently, the devices are
limited to patients with an indication for single-chamber ventricular
pacing. However, it is likely that wireless communication between
several implanted devices (e.g. atrial and ventricular leadless pace-
makers, or with a subcutaneous ICD), will open up new perspec-
tives in this therapy. Nevertheless, further data need to be
gathered regarding safety, long-term performance and extractabil-
ity of these devices, in order to ensure that the therapy lives up to its
promises.
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